# Revvity Inc. (RVTY) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $130.22, market value $14.5 billion.

## Valuation
- **P/E (trailing): 62.6×** (5-yr avg 34.5×, 3-yr avg 39.0×). Revvity Inc. trades at 62.6× trailing earnings, well above its own five-year average of 34.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 5.0×**. Each dollar of revenue is priced at 5.0×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 21.8×**. Enterprise value is 21.8× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 3.8%** (5-yr avg 3.5%). Free cash flow equals 3.8% of the market value, in line with its five-year average of 3.5%.
- **Earnings yield: 1.6%**. The inverse of the P/E: 1.6% of the price is earned each year.

## Profitability
- **Operating margin: 12.3%**. 12.3% of revenue is left after running the business.
- **Net margin: 8.4%**. 8.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 3.3%**. 3.3% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 3.0%**. Return on all capital, debt included, is 3.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 2.0%**. Each dollar of assets produces 2.0% of profit.

## Growth
- **Revenue growth (1 yr): 3.7%** (3-yr -4.8%/yr, 5-yr 1.4%/yr). Revenue grew 3.7% over the last year, against 1.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -5.9%** (3-yr -22.8%/yr, 5-yr -20.4%/yr). Earnings per share fell 5.9%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -5.0%/yr**. Free cash flow has compounded at -5.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.44**. Debt is 0.44 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 3.0×**. It would take 3.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.94**. A Z-score of 2.94 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.22%** ($0.28 per share, trailing). Revvity Inc. yields 0.22%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 14%** (6% of free cash flow). 14% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 0.0%/yr** (1-yr 0.0%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover Revvity Inc.; the consensus is buy, with an average price target of $125.25 (-4% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 52.4%** (YTD 34.9%, 3-mo 32.5%). The shares are up 52.4% over twelve months including dividends.
- **From 52-week high: -2.1%** (60.3% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 1.25** (volatility 38%). Beta of 1.25 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RVTY · Page: https://foliofundamentals.com/stocks/rvty

Not investment advice.